Bharat Immunologicals & Biologicals Valuation
Is 524663 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 524663 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 524663's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 524663's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524663?
Key metric: As 524663 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 524663's PS Ratio? | |
|---|---|
| PS Ratio | 13.3x |
| Sales | ₹76.50m |
| Market Cap | ₹1.02b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 21.9x |
| Enterprise Value/EBITDA | -8.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 524663's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.8x | ||
526139 Transgene Biotek | 55x | n/a | ₹484.9m |
NIRMAN Nirman Agri Genetics | 1.6x | n/a | ₹2.4b |
532039 Zenotech Laboratories | 12.7x | n/a | ₹4.7b |
514336 Genesis IBRC India | 5.9x | n/a | ₹216.3m |
524663 Bharat Immunologicals & Biologicals | 13.3x | n/a | ₹1.0b |
Price-To-Sales vs Peers: 524663 is good value based on its Price-To-Sales Ratio (13.3x) compared to the peer average (18.8x).
Price to Sales Ratio vs Industry
How does 524663's PS Ratio compare vs other companies in the Asian Biotechs Industry?
| 72 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 72 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 524663 is expensive based on its Price-To-Sales Ratio (13.3x) compared to the Asian Biotechs industry average (9x).
Price to Sales Ratio vs Fair Ratio
What is 524663's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 13.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 524663's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Caplin Point Laboratories
₹149.4b
Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.
CAPLIPOINT
₹1,963.75
7D
-1.3%
1Y
59.7%
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Sanofi India
₹139.4b
Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.
SANOFI
₹6,054.05
7D
-2.0%
1Y
-24.6%